The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Intervention(s) in this Clinical Trial

• Drug: fluoxetine
• Drug: sertraline
• Drug: citalopram
• Drug: escitalopram
• Drug: bupropion
• Drug: mirtazapine
• Drug: venlafaxine
• Drug: lithium
• Behavioral: Cognitive Behavioral Therapy

Inclusion Criteria:

• At least one suicide attempt or interrupted attempt within the past 45 days
• Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 12 Years

Maximum Age for this Clinical Trial: 18 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: National Institute of Mental Health (NIMH)

Overall Clinical Trial Officials and Contacts

Laurence Greenhill, MD Study Chair   

Information obtained from ClinicalTrials.gov on November 18, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00080158

Study ID Number: U10 MH66762

ClinicalTrials.gov Identifier: NCT00080158

Health Authority: United States: Food and Drug Administration